Hemab
Amalie Carnbring Bonde, PhD, serves as a Research Scientist at Hemab. Prior to joining the company, she worked as an industrial PhD student at Novo Nordisk. She holds a PhD in Molecular Biology from Aarhaus University Denmark.
This person is not in any offices
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.